Unveiling the Future of Molecular Imaging: Ashvattha Therapeutics Presents Groundbreaking Preclinical Data on 18FOP-801 PET Tracer at WMIC 2022
Ashvattha Therapeutics Announces Presentations of Preclinical Data on Hydroxyl Dendrimer-Based Imaging and Treatment Regimen in Multiple Sclerosis REDWOOD CITY, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing innovative therapies for neurological diseases, has announced that scientific collaborators at Stanford University will present data on an imaging and treatment regimen…